Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083883 · ClinicalTrials.gov registry record · Phase 1
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
A Phase 1 study of Synovial Sarcoma and Myxoid/Round Cell Liposarcoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06083883: Recruiting Phase 1 study of Synovial Sarcoma and Myxoid/Round Cell Liposarcoma, sponsored by M.D. Anderson Cancer Center.
NCT06083883 is a Phase 1 study of Synovial Sarcoma and Myxoid/Round Cell Liposarcoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 44 participants, below the 153-participant average among 11 other Synovial Sarcoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06083883, a Phase 1 study of Synovial Sarcoma and Myxoid/Round Cell Liposarcoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine phosphate
- DRUG NY-ESO-1 TCR/IL-15 NK
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
What NCT06083883 shows while recruiting
NCT06083883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 153-participant average among 11 other Synovial Sarcoma trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Synovial Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06083883 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06083883 about?
NCT06083883 is a clinical study titled "Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1". The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
What is the current status of trial NCT06083883?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2024-03-27. Estimated completion is 2028-11-30.
What conditions does trial NCT06083883 study?
This clinical trial studies the following conditions: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma.
What interventions are being tested in trial NCT06083883?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine phosphate (DRUG), NY-ESO-1 TCR/IL-15 NK (DRUG).
Who is sponsoring clinical trial NCT06083883?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06083883 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Synovial Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06083883's enrollment target sits among peer trials
44 6th of 11 higher than 6 of 11 other Synovial Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Synovial Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
SPEARHEAD-3 Pediatric Study
RECRUITING · Phase 1
-
MAGE-A4ᶜ¹º³²T for Multi-Tumor
ACTIVE NOT RECRUITING · Phase 1
-
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI